|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.49 USD | +2.55% |
|
+7.17% | +16.16% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 33.3 | +62.53% | 12 | ||||||
| 822.45 | +23.77% | 28 | ||||||
| 287.95 | +21.45% | 19 | ||||||
| 2,052,158.8 | +47.11% | 24 | ||||||
| 96.64 | +13.06% | 16 | ||||||
| 222.83 | +11.89% | 31 | ||||||
| 47.89 | -29.85% | 19 | ||||||
| 111.45 | -4.5% | 22 | ||||||
| 101.33 | +30.61% | 25 | ||||||
| 486.67 | +3.28% | 12 | ||||||
| 104.24 | +21.37% | 22 | ||||||
| 276.56 | +18.29% | 21 | ||||||
| 458,000 | +41.36% | 5 | ||||||
| 87.69 | +48.33% | 26 | ||||||
| 358.11 | -2.1% | 9 | ||||||
| - | - | 61.5 | +16.47% | 1 | ||||
| 14.4 | +61.68% | 12 | ||||||
| 72.5 | +9.07% | 2 | ||||||
| 30.05 | +92.32% | 9 | ||||||
| 77.7 | -14.27% | 10 | ||||||
| Average | 125,672.6 | +23.59% | 16 | ||||||
| Weighted average by Cap. | 225,632.57 | +19.53% | 20 |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
